Skip to content

My Evli online service will be upgraded on Thursday May 22, 2025 between 7.00 pm. and 8.00 pm. During this time, all online services will be unavailable. We apologize for any inconvenience.

Detection Technology - Good growth, some sales were postponed

DT’s Q1 result fell short of our expectations. All BUs grew, and total net sales experienced double-digit growth. The component shortage increasingly limited the growth, and part of the sales were postponed in all DT’s BUs.
  • Group results: Q1 net sales grew by 10.9% y/y to EUR 20.3m (EUR 21.1m/21.7m Evli/cons.) driven by all DT’s business units. Operating profit improved and grew by 9% y/y to EUR 1.5m (EUR 1.9m/2.1m Evli/cons.), indicating an EBIT margin of 7.4%. Soft scalability was driven by increased material costs and stronger investments into R&D to tackle the component shortage. Operative cashflow was down 39% y/y, totaling EUR 0.7m. R&D costs were 14.5% of net sales (Q1’21: 13.1%).
  • Medical (MBU): medical segment grew by 4.5% y/y to EUR 10.5m (Evli: EUR 10.9m). Growth was strong in CT applications both in developing and developed countries.
  • Security (SBU): security experienced an increase of 7.5% y/y, net sales totaling EUR 6.3m (Evli: EUR 7.3m). Despite the demand for aviation solutions has increased significantly, Q1 growth was still driven by applications other than those used in the aviation sector.
  • Industrial (IBU): net sales came in strong and grew by 45.2% y/y to 3.5m (Evli: EUR 2.9m). The demand was strong in all IBU’s main segments: imaging solutions for the food, pharmaceutical, and mining industries.
  • The company had ongoing project to design product modifications to its entire product portfolio to mitigate the challenges in the availability of special materials and electronic components.
  • FY’22 outlook: IBU and SBU to show double-digit growth in Q2 and MBU to decrease in Q2. Group net sales to grow by double-digit figures in Q2, H1 and H2.
Open Report